Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

Nadin Rabah, Fatima Ezzahra Ait Mohand, Nataly Kravchenko-Balasha*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The most prevalent and aggressive type of brain cancer, namely, glioblastoma (GBM), is characterized by intra- and inter-tumor heterogeneity and strong spreading capacity, which makes treatment ineffective. A true therapeutic answer is still in its infancy despite various studies that have made significant progress toward understanding the mechanisms behind GBM recurrence and its resistance. The primary causes of GBM recurrence are attributed to the heterogeneity and diffusive nature; therefore, monitoring the tumor’s heterogeneity and spreading may offer a set of therapeutic targets that could improve the clinical management of GBM and prevent tumor relapse. Additionally, the blood–brain barrier (BBB)-related poor drug delivery that prevents effective drug concentrations within the tumor is discussed. With a primary emphasis on signaling heterogeneity, tumor infiltration, and computational modeling of GBM, this review covers typical therapeutic difficulties and factors contributing to drug resistance development and discusses potential therapeutic approaches.

Original languageAmerican English
Article number14256
JournalInternational Journal of Molecular Sciences
Issue number18
StatePublished - 19 Sep 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.


  • GBM signaling
  • blood–brain barrier (BBB)
  • glioblastoma
  • heterogeneity
  • invasion
  • recurrence
  • targeted therapy


Dive into the research topics of 'Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers'. Together they form a unique fingerprint.

Cite this